TABLE 1.
Efficacy of E1224 treatment for 20 days in a Trypanosoma cruzi murine modela
| Exptl groupb | No. of surviving mice/total | No. of mice with negative FBEc/total | No. of mice with negative blood PCRd results/total | No. of mice with negative results/total (%) |
|---|---|---|---|---|
| E1224 | ||||
| 10 mg/kg | 7/7 | 7/7 | 7/7 | 7/7 (100) |
| 20 mg/kg | 7/7 | 6/7 | 5/6 | 5/7 (71.5) |
| 30 mg/kg | 7/7 | 7/7 | 5/7 | 6/7 (85.7) |
| 40 mg/kg | 7/7 | 7/7 | 6/7 | 5/7 (71.5) |
| 50 mg/kg | 7/7 | 6/7 | 5/6 | 6/7 (85.7) |
| Bz,f 100 mg/kg | 7/7 | 6/7 | 5/6 | 6/7 (85.7) |
| Untreated | 0/7 | 0/7 | NDe | 0/7 (0) |
| Uninfected | 7/7 | 7/7 | 7/7 | 7/7 (100) |
a
Swiss female mice (7/group) weighing 20 to 24 g were inoculated with 5 × 103 trypomastigotes (Y strain).
b
Oral treatment was initiated on the 4th day after inoculation and continued for 20 days.
c
FBE, fresh blood examination performed before and after cyclophosphamide immunosuppression.
d
PCR assay was performed at the 1st and 6th months after treatment.
e
ND, not detected (all mice died before the 30th day of infection).
f
Bz, benznidazole.